Evaluate Pharma

Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2028 for the global life science industry.

[Evaluate Pharma @evaluatepharma]

Over $500bn in prescription drug sales face generic competition by 2032. Which companies are most exposed, and what are they doing about it?

Find out in the Evaluate World Preview 2026: https://t.co/8IoWg6Yc75

[Evaluate Pharma @evaluatepharma]

Lilly is forecast to hit $137bn in annual drug sales by 2032. Download the Evaluate World Preview 2026 to see who's pulling ahead and why obesity and autoimmune are doing most of the heavy lifting.

Download it here: https://t.co/e3Xf1gSL63

[Evaluate Pharma @evaluatepharma]

The FDA approved 22 novel drugs in Q3 2026, the busiest quarter of the year so far and well ahead of Q2. Evaluate Pharma forecasts put the cohort at $31B in 2032 sales. Evaluate’s Paul Verdin looks at the new drugs ready to hit the market in Nature: https://t.co/xxtG9oy08T

[Evaluate Pharma @evaluatepharma]

Evaluate helps you navigate market trends—forecasts, competitive positioning, and more—to drive portfolio growth. Norstella connects R&D, market access, and commercialization, trusted by Top 100 pharma and industry experts. Follow @NorstellaCo to see how we complete the puzzle.

[Evaluate Pharma @evaluatepharma]

Every forecast change has a reason. Broker Assumptions in Evaluate Pharma links forecast movements to the underlying assumptions, while Ask Ella helps you uncover the why in seconds. Explain revisions in minutes, not hours. Log in: https://t.co/r8UFug1giP

[Evaluate Pharma @evaluatepharma]

Evaluate Spotlight Ep.04: Cardiovascular is live!

CV sales are forecast to grow 11% annually through 2032, driven by new entrants, launches, and emerging modalities. Hear from Mary Anderson and Jessica Merrill on the trends reshaping the market.

Watch: https://t.co/Qv6HpLUioT.

[Evaluate Pharma @evaluatepharma]

Evaluate Spotlight Ep.03: Immunology is live!

Explore the trends, deals, and innovations shaping one of pharma’s fastest-growing therapy areas.

▶️ Watch now: https://t.co/v15uc1xbvV

🔒 Up next: Cardiovascular | 19 Oct

[Evaluate Pharma @evaluatepharma]

The next opportunity may already be taking shape.

Value can move before the market fully catches up. Track the companies, assets and catalysts shaping biopharma to see where opportunity may be emerging next.

🎯 Stay ahead of market shifts: https://t.co/4FawtYPJQ4

[Evaluate Pharma @evaluatepharma]

Thousands of biopharma leaders start their month with Evaluate Discovery. Join them for sharp analysis, must-read insights, and the trends that matter, delivered monthly. Ready to be in the know? ✨ https://t.co/pIXfkVHgP7

[Evaluate Pharma @evaluatepharma]

Broker Assumptions is now live in Evaluate Pharma. It links forecast movements to the broker assumptions driving them, with Ask Ella giving you conversational access in seconds.

Log in now and just ask > https://t.co/txXyW363Q3

[Evaluate Pharma @evaluatepharma]

Last chance to register. Join Evaluate's CI leaders today at 3 PM BST / 10 AM ET for practical guidance on applying productivity benchmarks to competitor analysis. https://t.co/A5vAcQO6pO

[Evaluate Pharma @evaluatepharma]

Tomorrow, Evaluate's CI leaders will unpack the 2026 Pipeline-to-Patient Productivity Index and show how competitive intelligence teams can translate the macro findings to inform indication-level competitor analyses, leveraging real examples throughout. https://t.co/VzLR9ENOET

[Evaluate Pharma @evaluatepharma]

The people behind the platform make the difference. Atlas CI is built by experts with deep biopharma experience, helping turn complexity into confidence. Learn more: https://t.co/RVHwn9K3p2

[Evaluate Pharma @evaluatepharma]

"I consider myself an expert; I’ve been doing this for decades and can now do it in 10 minutes." – a Business Development Strategist at a global med-tech company on Atlas CI from @NorstellaCo, an AI agent for competitive intelligence.

Learn more: https://t.co/nP9iWV5KCQ

[Evaluate Pharma @evaluatepharma]

Drug approvals are taking longer, with median Phase I-to-approval timelines reaching 9.3 years. Join Evaluate's CI leaders on Oct. 13 to learn how to apply this insight to smarter competitor timeline forecasts. https://t.co/813h9kIWUk

[Evaluate Pharma @evaluatepharma]

The 2026 Pipeline-to-Patient Productivity Index reveals a key shift: the industry is failing earlier. Join Evaluate's CI experts on Oct. 13 to learn what this means for competitor pipeline analysis. https://t.co/cKha9fsBbI

[Evaluate Pharma @evaluatepharma]

What happens to the thesis when one assumption changes?

Pressure-test the forecasts, catalysts, competition, and market signals underpinning a company or asset.

Stress-test your assumptions. https://t.co/v32E28Hz30

[Evaluate Pharma @evaluatepharma]

From industry benchmarks to competitor-specific signals. Join Kelly Chamberlain & Adam Schaffner on Oct. 13 to see how CI teams can spot and act on critical pipeline trends. https://t.co/N7hwddHGy0

[Evaluate Pharma @evaluatepharma]

What’s the current oncology landscape? Ep. 02 of Evaluate Spotlight covers key insights: M&A is now targeted, ADCs and bispecifics have surged, half of top companies lack growth potential, and funding cuts may impact the early-stage pipeline.

▶️ Watch: https://t.co/a6JBxBkoP5

[Evaluate Pharma @evaluatepharma]

Weeks to months of competitive pipeline research. A skeptic did it in 10 minutes.

A Business Development Strategist with decades of experience got a very similar output from @NorstellaCo Atlas CI, an AI agent for competitive intelligence.

Learn more: https://t.co/c4GE0ctZMp